Dermatitis, Atopic clinical trials
The registry lists 1,591 studies for Dermatitis, Atopic across more than 10 countries. 286 are recruiting or about to start. 1,421 of them are mainly about Dermatitis, Atopic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
ClinicalTrials.gov finds 1,638 studies for Dermatitis, Atopic. How that becomes 1,590 here
This page counts the studies the registry files under Dermatitis, Atopic, and those it files under no condition that list Dermatitis, Atopicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,638Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −12List Dermatitis, Atopic as a condition, but the registry did not file them under itMost often written as “Atopic Dermatitis Eczema” (4), “Eczema Atopic Dermatitis” (4), and “Pruritus in Patients With Atopic Dermatitis” (1). The registry filed them under other conditions only, most often Eczema (5) and Psoriasis (4).
- −36Match it another way23 name it in the title and 13 by a synonym or other text the search reads.
- 1,590The count on this page70 of them list Dermatitis, Atopic in their own words; the registry filed them under no condition.
Get an email when these change. Save the Dermatitis, Atopic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Pfizer (57) · Sanofi (39) · LEO Pharma (36) · National Institute of Allergy and Infectious Diseases (NIAID) (35) · AbbVie (31) · Regeneron Pharmaceuticals (30) · Eli Lilly and Company (29) · Keymed Biosciences Co.Ltd (18)
What is being tested here
Drugs under test in Dermatitis, Atopic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Abrocitinib | 5 | 10 | 20 |
| Dupilumab | 4 | 12 | 50 |
| Crisaborole | 4 | 7 | 26 |
| Tacrolimus | 4 | 8 | 26 |
| Lebrikizumab | 4 | 17 | 24 |
| Roflumilast | 4 | 2 | 9 |
| Upadacitinib | 2 | 12 | 17 |
| Tralokinumab | 2 | 10 | 16 |
| Difamilast | 2 | 10 | 16 |
| Ruxolitinib | 2 | 6 | 15 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 12 open · JAK inhibitors 11 open · Calcineurin inhibitors 4 open · Corticosteroids 1 open · Antimetabolites 1 open
Coming up
131studies finish main data collection within a year24 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab · Phase 3 · AbbVie
- Nov 2026Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. · Phase 3 · medac GmbH
- Nov 2026ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis · Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd.
- Dec 2026A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis · Phase 3 · Otsuka Pharmaceutical Co., Ltd.
- Jan 2027Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis · Phase 3 · AbbVie
- Jan 2027Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis · Phase 3 · Shalamar Institute of Health Sciences
- Jan 2027A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · Shanghai Mabgeek Biotech.Co.Ltd
- Jan 2027A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) · Phase 3 · Turn Therapeutics
- Feb 2027A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis · Phase 3 · Otsuka Pharmaceutical Co., Ltd.
- Feb 2027A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis · Phase 3 · Keymed Biosciences Co.Ltd
Who these studies take
Of the 193 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 94 (49%) stop at 75 or younger. 93 (48%) take children under 18. 4 (2%) are for women only and 0 (0%) for men only; 51 (26%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 54 (28%) | 52 (27%) |
| 18 | 161 (83%) | 157 (81%) |
| 30 | 160 (83%) | 156 (81%) |
| 40 | 160 (83%) | 156 (81%) |
| 50 | 161 (83%) | 157 (81%) |
| 65 | 153 (79%) | 150 (78%) |
| 75 | 125 (65%) | 122 (63%) |
| 85 | 95 (49%) | 92 (48%) |
Across all 1,591 studies, recruiting or not: 59% stop at 75 or younger and 45% at 65; 45% take children; 1% are for women only and 1% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Dermatitis, Atopic studies take
Of 223 phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 14 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo5–20 · 131 studies | 12 mo5–20 · 114 studies | — |
| Phase 1/2 | 22 mo8–38 · 29 studies | 22 mo8–38 · 25 studies | — |
| Phase 2 | 14 mo10–19 · 223 studies | 13 mo9–17 · 195 studies | — |
| Phase 3 | 18 mo13–28 · 156 studies | 18 mo13–28 · 149 studies | — |
| Phase 4 | 25 mo14–41 · 45 studies | — | — |
| Interventional, no phase | 15 mo6–34 · 182 studies | 8 mo3–24 · 69 studies | 20 mo9–43 · 113 studies |
| Observational | 35 mo17–… · 170 studies | 32 mo11–84 · 74 studies | 61 mo19–… · 96 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 12, 2026.
Started recruiting6
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNov 6, 2026NCT07916480
- A Study Evaluating TRIV-573 in Atopic DermatitisOct 28, 2026NCT07782333
- PRA-216 Atopic Dermatitis Safety and Efficacy StudyOct 28, 2026NCT07810777
- Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisOct 16, 2026NCT07762833
- A Phase III Study of GS101 Injection to Dupixent®Oct 15, 2026NCT07386743
Show 1 moreShow fewer
Results posted5
- A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)Nov 10, 2026NCT05717920
- Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisNov 3, 2026NCT06058156
- A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsOct 23, 2026NCT06268860
- A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisOct 16, 2026NCT06280716
- A Study of LY3844583 in Healthy Participants and Participants With Atopic DermatitisOct 13, 2026NCT05486208
Stopped3
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisTerminatedOct 27, 2026NCT07330934
- Educational Eczema Video InterventionWithdrawnOct 19, 2026NCT03664271
- Dupilumab De-escalation in Pediatric Atopic DermatitisTerminatedOct 19, 2026NCT06116526
Newly registered15
- Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic DermatitisNov 10, 2026NCT07929181
- A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult ParticipantsNov 6, 2026NCT07920783
- A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic DermatitisNov 6, 2026NCT07920809
- Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and PsoriasisNov 5, 2026NCT07918560
- Localized Aeroallergen Exposure in Atopic DermatitisNov 5, 2026NCT07918586
Show 10 moreShow fewer
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationNov 5, 2026NCT07919899
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNov 4, 2026NCT07916480
- A Study for AR100DP1 in Mild to Moderate Atopic DermatitisNov 3, 2026NCT07914088
- Observational Analytical Validation Study of the Replior ScratchSenseNov 2, 2026NCT07909967
- ADBest TREAT RegistryOct 29, 2026NCT07904546
- A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic DermatitisOct 29, 2026NCT07904689
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisOct 29, 2026NCT07905547
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic DermatitisOct 26, 2026NCT07895615
- A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other TherapiesOct 21, 2026NCT07887867
- A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic DermatitisOct 14, 2026NCT07873801
Studies
Recruiting first, then most recently updated. Showing 50 of 1,591. Browse all 1,591 → or search them.
- A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07604324Phase 11 country
- Natural History and Genetics of Food Allergy and Related ConditionsRecruitingNCT025048531 country
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisRecruitingNCT07262983Phase 11 country
- Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics ProjectRecruitingNCT06300697Not applicable1 country
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisRecruitingNCT06311682Phase 313 countries
- Thera-Clean® Microbubbles System in Patients With Skin DiseasesEnrolling by invitationNCT07050810Early Phase 11 country
- Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresRecruitingNCT076458201 country
- Efficacy and Tolerability of a Probiotic OintmentNot yet recruitingNCT07701447Not applicable
- Effects of Treatments on Atopic DermatitisRecruitingNCT01631617Phase 21 country
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingNCT07783425Phase 34 countries
- First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisRecruitingNCT07527923Phase 12 countries
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisRecruitingNCT07916480Phase 31 country
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruitingNCT001772681 country
- A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic DermatitisNot yet recruitingNCT07920809Phase 1
- A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult ParticipantsNot yet recruitingNCT07920783Phase 11 country
- Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and PsoriasisNot yet recruitingNCT07918560Not applicable1 country
- Localized Aeroallergen Exposure in Atopic DermatitisNot yet recruitingNCT07918586Not applicable1 country
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationNot yet recruitingNCT07919899Phase 3
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaRecruitingNCT06807281Phase 37 countries
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsRecruitingNCT06564389Phase 12 countries
- Studies of Skin Microbes in Healthy People and in People With Skin ConditionsRecruitingNCT006058781 country
- A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaRecruitingNCT07216027Phase 29 countries
- A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07235384Phase 13 countries
- Observational Analytical Validation Study of the Replior ScratchSenseRecruitingNCT079099671 country
- A Study for AR100DP1 in Mild to Moderate Atopic DermatitisRecruitingNCT07914088Phase 21 country
- A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic DermatitisRecruitingNCT07003425Phase 29 countries
- Metabolic Profiling of Immune Responses in Immune-mediated DiseasesRecruitingNCT048648861 country
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic TreatmentRecruitingNCT072908039 countries
- Cardamom and Topical Roseomonas in Atopic DermatitisRecruitingNCT06096857Phase 21 country
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisNot yet recruitingNCT07905547Phase 4
- ADBest TREAT RegistryRecruitingNCT079045461 country
- A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic DermatitisNot yet recruitingNCT07904689Phase 11 country
- Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic DermatitisRecruitingNCT06934252Phase 12 countries
- A Study Evaluating TRIV-573 in Atopic DermatitisRecruitingNCT07782333Phase 23 countries
- Collection of Samples From Subjects With Various Skin Conditions and Healthy VolunteersRecruitingNCT059949761 country
- PRA-216 Atopic Dermatitis Safety and Efficacy StudyRecruitingNCT07810777Phase 22 countries
- Allergy, Asthma, and Atopic Eczema in FinlandEnrolling by invitationNCT063309741 country
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling by invitationNCT05735483Phase 313 countries
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic DermatitisRecruitingNCT07895615Phase 21 country
- Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234RecruitingNCT07453602Phase 11 country
- Digital Mindfulness Meditation in Adolescents With Atopic DermatitisRecruitingNCT07746427Not applicable1 country
- Microbiome in Atopic Dermatitis Under Systemic TherapyRecruitingNCT050993151 country
- A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other TherapiesNot yet recruitingNCT07887867
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisRecruitingNCT07690371Phase 31 country
- Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisRecruitingNCT07762833Phase 31 country
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeRecruitingNCT07242638Phase 21 country
- A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07754786Phase 31 country
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaRecruitingNCT07765888Phase 32 countries
- A Phase III Study of GS101 Injection to Dupixent®RecruitingNCT07386743Phase 31 country
- A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-UpRecruitingNCT067324141 country